Relapsed or Refractory Acute Myeloid Leukemia: Venetoclax and Alvocidib

Brief description of study

If you have been diagnosed with relapsed/refractory acute myeloid leukemia, you may qualify for this study. The main goal of this study is to see if the study drugs, venetoclax and alvocidib, can be safely combined for the treatment of patients with relapsed or refractory acute myeloid leukemia and produce meaningful anti-leukemia activity for patients.

Clinical Study Identifier: s18-00027 Identifier: NCT03441555
Principal Investigator: Mohammad Maher Abdul Hay
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.